| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Chih-Hsin Yang;Chen M.-C;Cheng A.-L;Hsu C.-H;Yeh K.-H;Yu Y.-C;Whang-Peng J;Yang P.-C.; CHIH-HSIN YANG; Chen M.-C; Cheng A.-L; Hsu C.-H; Yeh K.-H; Yu Y.-C; Whang-Peng J; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:26Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Hsu C.-H; Cheng J.C; Wang H.-P; Lee J.-M; Yeh K.-H; CHIH-HSIN YANG; Lin J.-T; Cheng A.-L; Lee Y.-C.; Lin C.-C;Hsu C.-H;Cheng J.C;Wang H.-P;Lee J.-M;Yeh K.-H;Chih-Hsin Yang;Lin J.-T;Cheng A.-L;Lee Y.-C.; Lin C.-C |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C;Yeh K.-H;Chih-Hsin Yang;Hsu C;Tsai Y.-C;Hsu W.-L;Cheng A.-L;Hsu C.-H.; Lin C.-C; Yeh K.-H; CHIH-HSIN YANG; Hsu C; Tsai Y.-C; Hsu W.-L; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Lu Y.-S;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Chih-Hsin Yang; Lin C.-C; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang C.-L; CHIH-HSIN YANG; Yeh K.-H; Hu F.-C; Chen K.-Y; Shih J.-Y; Lin Z.-Z; Yu C.-J; Cheng A.-L; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F; Chen I.-C; Hsu C; Chang S.-Y; Chien S.-F; Chen Y.-C; Hu F.-C; CHIH-HSIN YANG; Cheng A.-L; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:56Z |
Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
|
Chen L.T.;Chang J.Y;Chiang N.J;Yeh C.G;Wang Y.W;Shen B.N;Cheng A.L;Yeh K.H;Chih-Hsin Yang;Shiah H.S;Chang T.C; Chang T.C; Shiah H.S; CHIH-HSIN YANG; Yeh K.H; Cheng A.L; Shen B.N; Wang Y.W; Yeh C.G; Chiang N.J; Chang J.Y; Chen L.T. |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Cheng A.-L; Hsu C; Yang C.-H; Lu Y.-S; Chia-Chi Lin; Bu C.-F; Yeh K.-H.; Hsu C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Lee J.-M; Yeh K.-H; Yang C.-H; Lin J.-T; Cheng A.-L; Lee Y.-C.; Lee Y.-C.;Cheng A.-L;Lin J.-T;Yang C.-H;Yeh K.-H;Lee J.-M;Wang H.-P;Cheng J.C;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Cheng J.C; Wang H.-P |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Hsu C.-H.;Cheng A.-L;Hsu W.-L;Tsai Y.-C;Hsu C;Yang C.-H;Yeh K.-H;Chia-Chi Lin; Chia-Chi Lin; Yeh K.-H; Yang C.-H; Hsu C; Tsai Y.-C; Hsu W.-L; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:24Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W; Chia-Chi Lin; Huang T.-C; Cheng A.-L; Yeh K.-H; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:20Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C; Huang T.-C; Chia-Chi Lin; Hsieh M.-S; Chang C.-H; Huang P.-M; Lee J.-M; Hsu F.-M; Cheng J.C.-H; Wang H.-P; Yeh K.-H; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
Guo J.-C; Chia-Chi Lin; Huang T.-C; Huang P.-M; Kuo H.-Y; Chang C.-H; Wang C.-C; Cheng J.C.-H; Yeh K.-H; Hsu C.-H; Lee J.-M. |
| 臺大學術典藏 |
2020-05-25T07:35:10Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
Yang S.-H; Shao Y.-Y; Chia-Chi Lin; Kuo S.-H; Cheng A.-L; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:05Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Huang T.-C; Chia-Chi Lin; Wu Y.-C; Chia-Hsien Cheng J; Lee J.-M; Wang H.-P; Huang P.-M; Hsu F.-M; Yeh K.-H; Cheng A.-L; Tzen K.-Y; Hsu C.-H.; Hsu C.-H.;Tzen K.-Y;Cheng A.-L;Yeh K.-H;Hsu F.-M;Huang P.-M;Wang H.-P;Lee J.-M;Chia-Hsien Cheng J;Wu Y.-C;Chia-Chi Lin;Huang T.-C |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C; Yang C.-H; YEN-SHEN LU; Lin C.-C; Bu C.-F; Yeh K.-H.; Yeh K.-H.;Bu C.-F;Lin C.-C;Yen-Shen Lu;Yang C.-H;Hsu C;Cheng A.-L;Hsu C.-H; Hsu C.-H; Cheng A.-L |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Cheng A.-L.;Wu C.-Y;Hsu C.-H;Yang C.-H;Yeh K.-H;Kuo S.-H;Li C.-C;Hsu C;Yen-Shen Lu; YEN-SHEN LU; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
High-dose Tamoxifen Modulates Drug Resistance to Doxorubicin, Dacarbazine and Ifosfamide in Metastatic Uterine Leiomyosarcoma
|
Cheng A.-L.;Hsiao C.-H;Yen-Shen Lu;Yeh K.-H; Yeh K.-H; YEN-SHEN LU; Hsiao C.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.;Wu C.-Y;Chen J.-S;Li C.-C;Liu H.-T;Hsu C.-H;Yen-Shen Lu;Yeh K.-H;Yang C.-H;Shen Y.-C;Hsu C; Hsu C; Shen Y.-C; Yang C.-H; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H;Yen-Shen Lu;Hsu C.-H;Lin J.-F;Hsu C;Kuo S.-H;Li Jr. S;Cheng A.-L.; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Lin J.-F; Hsu C; Kuo S.-H; Li Jr. S; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H;Yen-Shen Lu;Hsu C.H;Lin J.F;Chao H.J;Huang T.C;Chung C.Y;Chang C.S;Yang C.H;Cheng A.L.; Yeh K.H; YEN-SHEN LU; Hsu C.H; Lin J.F; Chao H.J; Huang T.C; Chung C.Y; Chang C.S; Yang C.H; Cheng A.L. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors
|
Kuo M.-L; Kuo S.-H; Cheng A.-L.; Yeh K.-H; Yeh P.-Y; Lien H.-C; YEN-SHEN LU; Yen-Shen Lu;Lien H.-C;Yeh P.-Y;Yeh K.-H;Kuo M.-L;Kuo S.-H;Cheng A.-L. |
